MCVE.F Stock Overview
Provides healthcare and diagnostic services in Poland, Sweden, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Medicover AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr18.20 |
| 52 Week High | kr18.20 |
| 52 Week Low | kr11.26 |
| Beta | 1.45 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | 23.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 117.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| MCVE.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 48.6% | 1.5% | 1.6% |
| 1Y | 23.6% | 6.6% | 26.1% |
Return vs Industry: MCVE.F exceeded the US Healthcare industry which returned 4.9% over the past year.
Return vs Market: MCVE.F underperformed the US Market which returned 26.8% over the past year.
Price Volatility
| MCVE.F volatility | |
|---|---|
| MCVE.F Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MCVE.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MCVE.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 45,316 | Fredrik Rågmark | www.medicover.com |
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company’s Healthcare services includes service outpatient and inpatient care; dental services; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness services; hospital care; and preventive care. Its Diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology.
Medicover AB (publ) Fundamentals Summary
| MCVE.F fundamental statistics | |
|---|---|
| Market cap | US$2.75b |
| Earnings (TTM) | US$24.24m |
| Revenue (TTM) | US$1.98b |
113.5x
P/E Ratio1.4x
P/S RatioIs MCVE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCVE.F income statement (TTM) | |
|---|---|
| Revenue | €1.83b |
| Cost of Revenue | €1.45b |
| Gross Profit | €374.20m |
| Other Expenses | €351.90m |
| Earnings | €22.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 20.49% |
| Net Profit Margin | 1.22% |
| Debt/Equity Ratio | 112.3% |
How did MCVE.F perform over the long term?
See historical performance and comparison